These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31691066)

  • 1. Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis.
    Prentice A; Ruiz I; Weeda ER
    J Thromb Thrombolysis; 2020 Apr; 49(3):360-364. PubMed ID: 31691066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation.
    Nelson WW; Song X; Thomson E; Smith DM; Coleman CI; Damaraju CV; Schein JR
    Curr Med Res Opin; 2015; 31(10):1831-40. PubMed ID: 26211816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
    Deitelzweig S; Di Fusco M; Kang A; Savone M; Mokgokong R; Keshishian A; Gutierrez C; Cappelleri JC
    Curr Med Res Opin; 2021 Jun; 37(6):891-902. PubMed ID: 33686900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
    Coleman CI; Tangirala M; Evers T
    PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
    Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA
    BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
    Maura G; Pariente A; Alla F; Billionnet C
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
    Coleman CI; Bunz TJ; Ashton V
    Curr Med Res Opin; 2022 Jan; 38(1):19-26. PubMed ID: 34581258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
    Peng S; Deger KA; Ustyugova A; Gandhi P; Qiao N; Wang C; Kansal AR
    Curr Med Res Opin; 2018 Jan; 34(1):55-63. PubMed ID: 28862479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States.
    Coleman CI; Tangirala M; Evers T
    Int J Cardiol; 2016 Jun; 212():171-3. PubMed ID: 27038727
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.
    McHorney CA; Crivera C; Laliberté F; Germain G; Wynant W; Lefebvre P
    PLoS One; 2018; 13(4):e0194099. PubMed ID: 29621248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.
    Coleman C; Yuan Z; Schein J; Crivera C; Ashton V; Laliberté F; Lefebvre P; Peterson ED
    Curr Med Res Opin; 2017 Jun; 33(6):1033-1043. PubMed ID: 28366075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
    Mentias A; Shantha G; Chaudhury P; Vaughan Sarrazin MS
    JAMA Netw Open; 2018 Sep; 1(5):e182870. PubMed ID: 30646182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.